Biotech Analysts Van Buren, Werber and Bancroft, along with Dr. Warner, Director of Melanoma Program at Stanford Cancer Center and Dr. Atkins, Deputy Director of Georgetown Lombardi Comprehensive Cancer Center, discuss Moderna’s Phase II PCV data and BioNTech’s upcoming Ph2 combo data in 1L melanoma with Keytruda + BNT122 on an Analyst/Industry conference call to be held on April 17 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNA:
- TD Cowen biotech analysts to hold an analyst/industry conference call
- Moderna & Merck Are Better Together
- Merck, Moderna announce results from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
- Don’t Count Out Moderna Stock (NASDAQ:MRNA) for the Long Term
- Carisma Therapeutics initiated with an Outperform at Baird